Janux Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $10.0M | $10.6M | $8.1M | $8.6M | $3.6M |
| Operating income | -$157.7M | -$98.8M | -$73.0M | -$67.1M | -$32.9M |
| Cash from operations | -$82.2M | -$43.8M | -$50.6M | -$42.9M | -$17.0M |
| Capital expenditure | $1.0M | $359,000 | $1.9M | $6.4M | $1.5M |
| Free cash flow | -$83.3M | -$44.2M | -$52.4M | -$49.4M | -$18.5M |
| Impairments | — | — | — | $0 | $0 |
| Total assets | $1.0B | $1.1B | $380.4M | $364.0M | $379.8M |
| Total liabilities | $44.7M | $38.7M | $36.1M | $43.3M | $13.5M |
Shares outstanding 61.0M · Free float 76.5%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.